Literature DB >> 24895878

Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial.

Andrew M Demchuk1, Mayank Goyal, Sharon D Yeatts, Janice Carrozzella, Lydia D Foster, Emmad Qazi, Michael D Hill, Tudor G Jovin, Marc Ribo, Bernard Yan, Osama O Zaidat, Donald Frei, Rüdiger von Kummer, Kevin M Cockroft, Pooja Khatri, David S Liebeskind, Thomas A Tomsick, Yuko Y Palesch, Joseph P Broderick.   

Abstract

PURPOSE: To use baseline computed tomographic (CT) angiography to analyze imaging and clinical end points in an Interventional Management of Stroke III cohort to identify patients who would benefit from endovascular stroke therapy.
MATERIALS AND METHODS: The primary clinical end point was 90-day dichotomized modified Rankin Scale (mRS) score. Secondary end points were 90-day mRS score distribution and 24-hour recanalization. Prespecified subgroup was baseline proximal occlusions (internal carotid, M1, or basilar arteries). Exploratory analyses were subsets with any occlusion and specific sites of occlusion (two-sided α = .01).
RESULTS: Of 656 subjects, 306 (47%) underwent baseline CT angiography or magnetic resonance angiography. Of 306, 282 (92%) had arterial occlusions. At baseline CT angiography, proximal occlusions (n = 220) demonstrated no difference in primary outcome (41.3% [62 of 150] endovascular vs 38% [27 of 70] intravenous [IV] tissue-plasminogen activator [tPA]; relative risk, 1.07 [99% confidence interval: 0.67, 1.70]; P = .70); however, 24-hour recanalization rate was higher for endovascular treatment (n = 167; 84.3% [97 of 115] endovascular vs 56% [29 of 52] IV tPA; P < .001). Exploratory subgroup analysis for any occlusion at baseline CT angiography did not demonstrate significant differences between endovascular and IV tPA arms for primary outcome (44.7% [85 of 190] vs 38% [35 of 92], P = .29), although ordinal shift analysis of full mRS distribution demonstrated a trend toward more favorable outcome (P = .011). Carotid T- or L-type occlusion (terminal internal carotid artery [ICA] with M1 middle cerebral artery and/or A1 anterior cerebral artery involvement) or tandem (extracranial or intracranial) ICA and M1 occlusion subgroup also showed a trend favoring endovascular treatment over IV tPA alone for primary outcome (26% [12 of 46] vs 4% [one of 23], P = .047).
CONCLUSION: Significant differences were identified between treatment arms for 24-hour recanalization in proximal occlusions; carotid T- or L-type and tandem ICA and M1 occlusions showed greater recanalization and a trend toward better outcome with endovascular treatment. Vascular imaging should be mandated in future endovascular trials to identify such occlusions. Online supplemental material is available for this article. © RSNA, 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24895878      PMCID: PMC4174723          DOI: 10.1148/radiol.14132649

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  24 in total

1.  Recanalization after thrombolysis in stroke patients: predictors and prognostic implications.

Authors:  A Zangerle; S Kiechl; M Spiegel; M Furtner; M Knoflach; P Werner; A Mair; G Wille; C Schmidauer; K Gautsch; T Gotwald; S Felber; W Poewe; J Willeit
Journal:  Neurology       Date:  2007-01-02       Impact factor: 9.910

2.  Conscious sedation versus general anesthesia during endovascular therapy for acute anterior circulation stroke: preliminary results from a retrospective, multicenter study.

Authors:  Alex Abou-Chebl; Ridwan Lin; Muhammad Shazam Hussain; Tudor G Jovin; Elad I Levy; David S Liebeskind; Albert J Yoo; Daniel P Hsu; Marilyn M Rymer; Ashis H Tayal; Osama O Zaidat; Sabareesh K Natarajan; Raul G Nogueira; Ashish Nanda; Melissa Tian; Qing Hao; Junaid S Kalia; Thanh N Nguyen; Michael Chen; Rishi Gupta
Journal:  Stroke       Date:  2010-04-15       Impact factor: 7.914

3.  Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials.

Authors:  Alexander C Flint; Gary R Duckwiler; Ronald F Budzik; David S Liebeskind; Wade S Smith
Journal:  Stroke       Date:  2007-03-01       Impact factor: 7.914

4.  Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke.

Authors:  Maher Saqqur; Ken Uchino; Andrew M Demchuk; Carlos A Molina; Zsolt Garami; Sergio Calleja; Naveed Akhtar; Finton O Orouk; Abdul Salam; Ashfaq Shuaib; Andrei V Alexandrov
Journal:  Stroke       Date:  2007-02-08       Impact factor: 7.914

5.  The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET).

Authors:  Deidre A De Silva; Caspar Brekenfeld; Martin Ebinger; Søren Christensen; P Alan Barber; Kenneth S Butcher; Christopher R Levi; Mark W Parsons; Christopher F Bladin; Geoffrey A Donnan; Stephen M Davis
Journal:  Stroke       Date:  2010-01-07       Impact factor: 7.914

6.  Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents.

Authors:  G J Dehmer; N Gresalfi; D Daly; B Oberhardt; D A Tate
Journal:  J Am Coll Cardiol       Date:  1995-04       Impact factor: 24.094

7.  Methodology of the Interventional Management of Stroke III Trial.

Authors:  Pooja Khatri; Michael D Hill; Yuko Y Palesch; Judith Spilker; Edward C Jauch; Janice A Carrozzella; Andrew M Demchuk; Renee' Martin; Patrick Mauldin; Catherine Dillon; Karla J Ryckborst; Scott Janis; Thomas A Tomsick; Joseph P Broderick
Journal:  Int J Stroke       Date:  2008-05       Impact factor: 5.266

8.  In vivo effects of contrast media on coronary thrombolysis.

Authors:  S Pislaru; C Pislaru; M Szilard; J Arnout; F Van de Werf
Journal:  J Am Coll Cardiol       Date:  1998-10       Impact factor: 24.094

9.  Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator.

Authors:  Italo Linfante; Rafael H Llinas; Magdy Selim; Claudia Chaves; Sandeep Kumar; Robert A Parker; Louis R Caplan; Gottfried Schlaug
Journal:  Stroke       Date:  2002-08       Impact factor: 7.914

10.  Protocol for the perfusion and angiography imaging sub-study of the Third International Stroke Trial (IST-3) of alteplase treatment within six-hours of acute ischemic stroke.

Authors:  Joanna M Wardlaw; Rudiger von Kummer; Trevor Carpenter; Mark Parsons; Richard I Lindley; Geoff Cohen; Veronica Murray; Adam Kobayashi; Andre Peeters; Francesca Chappell; Peter A G Sandercock
Journal:  Int J Stroke       Date:  2013-01-22       Impact factor: 5.266

View more
  54 in total

1.  Endovascular Therapy Demonstrates Benefit over Intravenous Recombinant Tissue Plasminogen Activator Based on Repeatedly Measured National Institutes of Health Stroke Scale.

Authors:  Liqiong Fan; Sharon D Yeatts; Lydia D Foster; Pooja Khatri; Thomas Tomsick; Joseph P Broderick; Yuko Y Palesch
Journal:  Interv Neurol       Date:  2016-10-19

Review 2.  Endovascular Treatment versus Best Medical Treatment in Patients with Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.

Authors:  A I Qureshi; M F Ishfaq; H A Rahman; A P Thomas
Journal:  AJNR Am J Neuroradiol       Date:  2016-04-21       Impact factor: 3.825

3.  Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke: Pooled Analysis of Interventional Management of Stroke III and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands Data.

Authors:  Joseph P Broderick; Olvert A Berkhemer; Yuko Y Palesch; Diederik W J Dippel; Lydia D Foster; Yvo B W E M Roos; Aad van der Lugt; Thomas A Tomsick; Charles B L M Majoie; Wim H van Zwam; Andrew M Demchuk; Robert J van Oostenbrugge; Pooja Khatri; Hester F Lingsma; Michael D Hill; Bob Roozenbeek; Edward C Jauch; Tudor G Jovin; Bernard Yan; Rüdiger von Kummer; Carlos A Molina; Mayank Goyal; Wouter J Schonewille; Mikael Mazighi; Stefan T Engelter; Craig S Anderson; Judith Spilker; Janice Carrozzella; Karla J Ryckborst; L Scott Janis; Kit N Simpson
Journal:  Stroke       Date:  2015-10-20       Impact factor: 7.914

4.  Histopathological Characteristics of IV Recombinant Tissue Plasminogen -Resistant Thrombi in Patients with Acute Ischemic Stroke.

Authors:  Adnan I Qureshi; Mushtaq H Qureshi; Iryna Lobanova; Asif Bashir; Asif A Khan; Stephen M Bologna; Michelle Peterson; M Fareed K Suri
Journal:  J Vasc Interv Neurol       Date:  2016-01

Review 5.  Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials.

Authors:  Joseph P Broderick; Opeolu Adeoye; Jordan Elm
Journal:  Stroke       Date:  2017-06-16       Impact factor: 7.914

6.  Power of an Adaptive Trial Design for Endovascular Stroke Studies: Simulations Using IMS (Interventional Management of Stroke) III Data.

Authors:  Maarten G Lansberg; Ninad S Bhat; Sharon D Yeatts; Yuko Y Palesch; Joseph P Broderick; Gregory W Albers; Tze L Lai; Philip W Lavori
Journal:  Stroke       Date:  2016-11-15       Impact factor: 7.914

7.  R2* Map by IDEAL IQ for Acute Cerebral Infarction: Compared with Susceptibility Vessel Sign on T2*-Weighted Imaging.

Authors:  Yuki Shinohara; Ayumi Kato; Eijiro Yamashita; Toshihide Ogawa
Journal:  Yonago Acta Med       Date:  2016-09-12       Impact factor: 1.641

8.  Multimodal CT Imaging: Time to Treatment and Outcomes in the IMS III Trial.

Authors:  A Vagal; L D Foster; B Menon; A Livorine; J Shi; E Qazi; S D Yeatts; A M Demchuk; M D Hill; T A Tomsick; M Goyal
Journal:  AJNR Am J Neuroradiol       Date:  2016-03-17       Impact factor: 3.825

Review 9.  Thrombectomy for Acute Ischemic Stroke: Recent Insights and Future Directions.

Authors:  Aravind Ganesh; Mayank Goyal
Journal:  Curr Neurol Neurosci Rep       Date:  2018-07-23       Impact factor: 5.081

10.  Collateral Clock Is More Important Than Time Clock for Tissue Fate.

Authors:  Achala Vagal; Richard Aviv; Heidi Sucharew; Mahati Reddy; Qinghua Hou; Patrik Michel; Tudor Jovin; Thomas Tomsick; Max Wintermark; Pooja Khatri
Journal:  Stroke       Date:  2018-09       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.